eBioscience is a biotechnology company founded in 2009, headquartered in the United States. The company, acquired by Affymetrix, focuses on integrating genomics, proteomics, and pathways biology to develop personalized medicine. Their emphasis on understanding single cells at a molecular level for improved clinical treatments and health outcomes sets them apart in the industry.
One of its significant achievements includes obtaining a $55.00M Venture Round investment on 11 February 2011 from GE Capital. Their comprehensive solution offering empowers scientists in assessing molecular and cellular networks in various fields such as immunology, cell biology, oncology, stem cell biology, and clinical diagnostics. As a frontrunner in providing critical reagents, eBioscience contributes to new discoveries in life sciences through a diverse range of antibodies, ELISAs, and proteins used in research and clinical applications.
Given its substantial market presence and continuous innovation in the biotechnology and healthcare industries, eBioscience, now part of Affymetrix, positions itself as an attractive investment opportunity with the potential to revolutionize personalized medicine and advance life science discoveries.
No recent news or press coverage available for eBioscience.